• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks

    Novo Nordisk Files for Regulatory Approval of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes

    Chelsea Pratt
    Dec. 05, 2016 08:38AM PST
    Life Science Investing News

    Novo Nordisk today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for semaglutide, a glucagon-like peptide-1 analog administered once-weekly, for the treatment of adults with type 2 diabetes.

    Novo Nordisk today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for semaglutide, a glucagon-like peptide-1 (GLP-1) analog administered once-weekly, for the treatment of adults with type 2 diabetes.  The company also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for semaglutide.
    The submission is based on the results from the SUSTAIN clinical trial program which included more than 8,000 adults with type 2 diabetes. In the SUSTAIN program, once-weekly semaglutide was studied in combination with oral-antidiabetic agents and in combination with basal insulin. Semaglutide demonstrated statistically significant and sustained blood glucose control compared to sitagliptin, exenatide extended-release, once-daily insulin glargine U100 and placebo. Weight loss, a secondary endpoint, was also demonstrated in all semaglutide arms of the SUSTAIN program.  Furthermore, the cardiovascular outcomes trial, SUSTAIN 6, demonstrated a cardiovascular risk reduction compared to placebo, as add-on to standard of care in patients with high cardiovascular risk.
    Across the SUSTAIN clinical trial program, the most common adverse events >5% were nausea, vomiting, diarrhea, abdominal pain and constipation.
    “Achieving blood glucose control, weight loss and reducing the risk of cardiovascular events remains a significant challenge for adults with type 2 diabetes,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “We are excited with this regulatory filing as results from the SUSTAIN program show that once-weekly semaglutide has the potential to offer further improvement for adults in their treatment of type 2 diabetes.”
    About semaglutide
    Semaglutide is a once-weekly analog of human GLP-1 that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. Novo Nordisk intends to make semaglutide available in a prefilled delivery device based on the same technology platform as FlexTouch®.
    About the SUSTAIN phase 3a clinical trial program
    SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a global clinical trial development program for the treatment of type 2 diabetes. The study was comprised of eight Phase 3a studies of semaglutide encompassing more than 8,000 subjects around the globe.
    About Novo Nordisk
    Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has nearly 5,000 employees in the United States. For more information, visit novonordisk.us or follow us on Twitter: @novonordiskus.
    Logo – https://photos.prnewswire.com/prnh/20110414/NY80976LOGO
    SOURCE Novo Nordisk

    marketing authorization\food and drug administration
    The Conversation (0)

    Go Deeper

    AI Powered
    Medicine capsule showing active ingredients.

    5 Biggest Pharma Stocks

    Scientist with petri dish.

    Pharma Market Forecast: Top Trends for Pharma in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×